Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non–Small-Cell Lung Cancer
Saved in:
| Published in | Clinical lung cancer Vol. 22; no. 1; pp. e54 - e56 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Elsevier Inc
01.01.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Author | Chic, Nuria Mezquita, Laura Chebib, Ralph Besse, Benjamin Aldea, Mihaela Caramella, Caroline Planchard, David |
|---|---|
| Author_xml | – sequence: 1 givenname: Nuria surname: Chic fullname: Chic, Nuria organization: Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain – sequence: 2 givenname: Laura surname: Mezquita fullname: Mezquita, Laura organization: Medical Oncology Department, Gustave Roussy, Villejuif, France – sequence: 3 givenname: Mihaela orcidid: 0000-0001-7685-051X surname: Aldea fullname: Aldea, Mihaela organization: Medical Oncology Department, Gustave Roussy, Villejuif, France – sequence: 4 givenname: Ralph surname: Chebib fullname: Chebib, Ralph organization: Medical Oncology Department, Gustave Roussy, Villejuif, France – sequence: 5 givenname: Caroline surname: Caramella fullname: Caramella, Caroline organization: Radiology Department, Gustave Roussy, Villejuif, France – sequence: 6 givenname: David surname: Planchard fullname: Planchard, David organization: Medical Oncology Department, Gustave Roussy, Villejuif, France – sequence: 7 givenname: Benjamin surname: Besse fullname: Besse, Benjamin email: benjamin.besse@gustaveroussy.fr organization: Medical Oncology Department, Gustave Roussy, Villejuif, France |
| BookMark | eNp9kEtu2zAQhrlIgCZOL9AVLyCFD4uygGxc5dEAdlvUbrYENRomNGgpIKkk3vUOWeR-PUllOF1009VgBv83-PGdkqOu75CQT5zlnHF1vsnBe8gFEyxnZc64PCInvBBFVko2_UBOY9wwJpTk4oS8rQYAjNEOnq6eXYIHmnp6h9shGIuda-h3P0Ra943bYnL7w9wmDPTSNP8k1sH8Daz7Fwcu7ajr6Ocf8-s7xdhVthyS6RJdYjIxmeSAfu27379eV1vjfVaj93QxdPe0Nh1gOCPH1viIH9_nhPy8vlrXX7LFt5vber7IgM8qmalKSTtT0IpGwhSaRnALRWmrqpq2qmJiXKRRRs5soywyybmUWJbAi3Yq2kJOiDj8hdDHGNDqx-C2Juw0Z3qvU2_0Xqfe69Ss1KPOEbo4QDg2e3IYdASHY-3WBYSk2979D_8D_OeEWQ |
| CitedBy_id | crossref_primary_10_1007_s40278_021_92976_7 crossref_primary_10_1016_j_ctrv_2021_102335 crossref_primary_10_3390_cancers15051426 crossref_primary_10_1002_ijc_35070 |
| Cites_doi | 10.1016/S0140-6736(16)00004-0 10.1016/S1470-2045(18)30142-6 10.1016/j.jtho.2018.08.302 10.1200/PO.18.00266 10.3390/cancers11121950 10.1177/1758834014566428 10.1016/j.jtho.2018.04.024 10.1016/S1470-2045(17)30679-4 10.1634/theoncologist.2016-0456 10.1016/S1470-2045(16)30122-X 10.1016/j.ejca.2019.07.016 10.1016/j.ctrv.2018.04.006 10.1158/1078-0432.CCR-18-2062 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier Inc. |
| Copyright_xml | – notice: 2020 Elsevier Inc. |
| DBID | AAYXX CITATION |
| DOI | 10.1016/j.cllc.2020.07.013 |
| DatabaseName | CrossRef |
| DatabaseTitle | CrossRef |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | e56 |
| ExternalDocumentID | 10_1016_j_cllc_2020_07_013 S1525730420302357 |
| GroupedDBID | --- --K --M .1- .FO .XZ .~1 0R~ 1P~ 1~. 29B 4.4 457 4G. 53G 5GY 5VS 6J9 6PF 7-5 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXKI AAXUO ABBQC ABFNM ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEGXH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV C45 CAG COF DU5 EBS EFJIC EJD EMB EMOBN F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MET MO0 O-L O9- OAUVE OBH OC~ OHH OO- OVD P-8 P-9 PC. Q38 R2- ROL SDF SEL SES SPCBC SSH SSZ SV3 T5K TEORI UDS Z5R ~G- AAYXX CITATION |
| ID | FETCH-LOGICAL-c1893-6963f86cd2b3c4cbb21fc57f9994d6902c573a6a38fb6fe031133e77c15d42d53 |
| IEDL.DBID | .~1 |
| ISSN | 1525-7304 |
| IngestDate | Thu Sep 26 18:13:27 EDT 2024 Tue Oct 01 07:16:38 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | BRAF inhibitor MEK inhibitor NSCLC Interstitial lung disease |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c1893-6963f86cd2b3c4cbb21fc57f9994d6902c573a6a38fb6fe031133e77c15d42d53 |
| ORCID | 0000-0001-7685-051X |
| OpenAccessLink | http://www.clinical-lung-cancer.com/article/S1525730420302357/pdf |
| ParticipantIDs | crossref_primary_10_1016_j_cllc_2020_07_013 elsevier_sciencedirect_doi_10_1016_j_cllc_2020_07_013 |
| PublicationCentury | 2000 |
| PublicationDate | January 2021 2021-01-00 |
| PublicationDateYYYYMMDD | 2021-01-01 |
| PublicationDate_xml | – month: 01 year: 2021 text: January 2021 |
| PublicationDecade | 2020 |
| PublicationTitle | Clinical lung cancer |
| PublicationYear | 2021 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Greco, Safi, Swami, Ginader, Milhem, Zakharia (bib5) 2019; 11 Barlesi, Mazieres, Merlio (bib1) 2016; 387 Dagogo-Jack, Martinez, Yeap (bib6) 2019; 25 Daud, Tsai (bib4) 2017; 22 Planchard, Smit, Groen (bib3) 2017; 18 Mazieres, Montané, Barlesi (bib8) 2018; 13 Leonetti, Facchinetti, Rossi (bib2) 2018; 66 Ascierto, McArthur, Dreno (bib10) 2016; 17 Dudnik, Peled, Nechushtan (bib7) 2018; 13 Welsh, Corrie (bib11) 2015; 7 Gogas, Flaherty, Dummer (bib13) 2019; 119 Dummer, Ascierto, Gogas (bib12) 2018; 19 Subbiah, Gervais, Riely (bib9) 2019 Gogas (10.1016/j.cllc.2020.07.013_bib13) 2019; 119 Dummer (10.1016/j.cllc.2020.07.013_bib12) 2018; 19 Planchard (10.1016/j.cllc.2020.07.013_bib3) 2017; 18 Daud (10.1016/j.cllc.2020.07.013_bib4) 2017; 22 Welsh (10.1016/j.cllc.2020.07.013_bib11) 2015; 7 Dagogo-Jack (10.1016/j.cllc.2020.07.013_bib6) 2019; 25 Greco (10.1016/j.cllc.2020.07.013_bib5) 2019; 11 Subbiah (10.1016/j.cllc.2020.07.013_bib9) 2019 Ascierto (10.1016/j.cllc.2020.07.013_bib10) 2016; 17 Leonetti (10.1016/j.cllc.2020.07.013_bib2) 2018; 66 Barlesi (10.1016/j.cllc.2020.07.013_bib1) 2016; 387 Dudnik (10.1016/j.cllc.2020.07.013_bib7) 2018; 13 Mazieres (10.1016/j.cllc.2020.07.013_bib8) 2018; 13 |
| References_xml | – volume: 13 start-page: 1128 year: 2018 end-page: 1137 ident: bib7 article-title: mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors publication-title: J Thorac Oncol contributor: fullname: Nechushtan – volume: 17 start-page: 1248 year: 2016 end-page: 1260 ident: bib10 article-title: Cobimetinib combined with vemurafenib in advanced publication-title: Lancet Oncol contributor: fullname: Dreno – volume: 19 start-page: 603 year: 2018 end-page: 615 ident: bib12 article-title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with publication-title: Lancet Oncol contributor: fullname: Gogas – volume: 387 start-page: 1415 year: 2016 end-page: 1426 ident: bib1 article-title: Routine molecular profiling of patients with advanced non–small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) publication-title: Lancet contributor: fullname: Merlio – volume: 119 start-page: 97 year: 2019 end-page: 106 ident: bib13 article-title: Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management publication-title: Eur J Cancer contributor: fullname: Dummer – volume: 7 start-page: 122 year: 2015 end-page: 136 ident: bib11 article-title: Management of publication-title: Ther Adv Med Oncol contributor: fullname: Corrie – volume: 22 start-page: 823 year: 2017 end-page: 833 ident: bib4 article-title: Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma publication-title: Oncologist contributor: fullname: Tsai – volume: 66 start-page: 82 year: 2018 end-page: 94 ident: bib2 article-title: in non–small cell lung cancer (NSCLC): pickaxing another brick in the wall publication-title: Cancer Treat Rev contributor: fullname: Rossi – volume: 18 start-page: 1307 year: 2017 end-page: 1316 ident: bib3 article-title: Dabrafenib plus trametinib in patients with previously untreated publication-title: Lancet Oncol contributor: fullname: Groen – volume: 13 start-page: S348 year: 2018 end-page: S349 ident: bib8 article-title: OA12.05 Vemurafenib in patients harboring V600 and non V600 publication-title: J Thorac Oncol contributor: fullname: Barlesi – year: 2019 ident: bib9 article-title: Efficacy of vemurafenib in patients with non–small-cell lung cancer with publication-title: JCO Precis Oncol contributor: fullname: Riely – volume: 11 start-page: 1950 year: 2019 ident: bib5 article-title: Efficacy and adverse events in metastatic melanoma patients treated with combination publication-title: Cancers (Basel) contributor: fullname: Zakharia – volume: 25 start-page: 158 year: 2019 end-page: 165 ident: bib6 article-title: Impact of publication-title: Clin Cancer Res contributor: fullname: Yeap – volume: 387 start-page: 1415 year: 2016 ident: 10.1016/j.cllc.2020.07.013_bib1 article-title: Routine molecular profiling of patients with advanced non–small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) publication-title: Lancet doi: 10.1016/S0140-6736(16)00004-0 contributor: fullname: Barlesi – volume: 19 start-page: 603 year: 2018 ident: 10.1016/j.cllc.2020.07.013_bib12 article-title: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30142-6 contributor: fullname: Dummer – volume: 13 start-page: S348 year: 2018 ident: 10.1016/j.cllc.2020.07.013_bib8 article-title: OA12.05 Vemurafenib in patients harboring V600 and non V600 BRAF mutations: final results of the NSCLC cohort from the AcSé trial publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.08.302 contributor: fullname: Mazieres – year: 2019 ident: 10.1016/j.cllc.2020.07.013_bib9 article-title: Efficacy of vemurafenib in patients with non–small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study publication-title: JCO Precis Oncol doi: 10.1200/PO.18.00266 contributor: fullname: Subbiah – volume: 11 start-page: 1950 year: 2019 ident: 10.1016/j.cllc.2020.07.013_bib5 article-title: Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: a systematic review publication-title: Cancers (Basel) doi: 10.3390/cancers11121950 contributor: fullname: Greco – volume: 7 start-page: 122 year: 2015 ident: 10.1016/j.cllc.2020.07.013_bib11 article-title: Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma publication-title: Ther Adv Med Oncol doi: 10.1177/1758834014566428 contributor: fullname: Welsh – volume: 13 start-page: 1128 year: 2018 ident: 10.1016/j.cllc.2020.07.013_bib7 article-title: BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2018.04.024 contributor: fullname: Dudnik – volume: 18 start-page: 1307 year: 2017 ident: 10.1016/j.cllc.2020.07.013_bib3 article-title: Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non–small-cell lung cancer: an open-label, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(17)30679-4 contributor: fullname: Planchard – volume: 22 start-page: 823 year: 2017 ident: 10.1016/j.cllc.2020.07.013_bib4 article-title: Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma publication-title: Oncologist doi: 10.1634/theoncologist.2016-0456 contributor: fullname: Daud – volume: 17 start-page: 1248 year: 2016 ident: 10.1016/j.cllc.2020.07.013_bib10 article-title: Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30122-X contributor: fullname: Ascierto – volume: 119 start-page: 97 year: 2019 ident: 10.1016/j.cllc.2020.07.013_bib13 article-title: Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.07.016 contributor: fullname: Gogas – volume: 66 start-page: 82 year: 2018 ident: 10.1016/j.cllc.2020.07.013_bib2 article-title: BRAF in non–small cell lung cancer (NSCLC): pickaxing another brick in the wall publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2018.04.006 contributor: fullname: Leonetti – volume: 25 start-page: 158 year: 2019 ident: 10.1016/j.cllc.2020.07.013_bib6 article-title: Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-2062 contributor: fullname: Dagogo-Jack |
| SSID | ssj0026312 |
| Score | 2.2862074 |
| SourceID | crossref elsevier |
| SourceType | Aggregation Database Publisher |
| StartPage | e54 |
| SubjectTerms | BRAF inhibitor Interstitial lung disease MEK inhibitor NSCLC |
| Title | Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non–Small-Cell Lung Cancer |
| URI | https://dx.doi.org/10.1016/j.cllc.2020.07.013 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NTtwwELYQlRCXqpSiAgX5wA2lu7FjB45LYLXtsivELj-3yHZsKSiboG2iwgX1HTj0_foknUmyCCTEgVMUy44iz_jzN_b8ELKnhJamK5WXJHjNKI3wDi1YKc4GIeZyMVLjOeRoLAcXwc9rcb1EokUsDLpVttjfYHqN1m1Lp53Nzm2adiZYuSdEa7zL66QtGMEO2x_o9PeHJzcPJnlz4ymwbCv0bgNnGh8vk2WYxpB16wSePn99c3q24fQ_kY8tU6S95mfWyJLNP5OVUXsXvk7-Tqq62KGrMjr5ncLs07Kgl3ZWzZWzearpWVb9olGh0xnGNUNDDwuC02OlX_SYon9W02Fa3MHXy3ua5vTovNe_BKJy4o0qLDVMR7ZUGH-UGjou8n9_HiczlWVeZLOMngJm0Ag1aP6FXPRPptHAa8sseMYHtuJJWIPuQJqEaW4CozXznRGhA-oYJGA8M3jhSip-4LR0FlAA7FobhsYXScASwTfIcl7k9iuhIRAK54eA_5IHQulDyVjiu4ADLbQqsJtkfzG_8W2TTSNeuJndxCiNGKURd8MYpLFJxEIE8QudiAHu3xi39c5x22SVocdKfcDyjSyX88ruAOUo9W6tU7vkQ-_HcDDG5_D8avgfUpnX6A |
| link.rule.ids | 315,783,787,4509,24128,27936,27937,45597,45691 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1PT9swFLcYSGyXaQwQZWz4sBuK2sSxQ49dRlVGU020IG6W7dhSUJqgLhHbbd9hh30_PsneS9IJJLTDjrH8rMjv-fn3_P4R8lFxLcxAKC9N0c0oDPeGFqwUZ8MIa7kYofEdMpmJyVX45YbfbJB4nQuDYZWd7m91eqOtu5F-t5v9uyzrz7FzT4TW-IA1RVtekC1AA0M4nVuj84vJ7K_dJVjr9OTYuRUIutyZNszL5DlWMgwGTQ1Pnz1_Pz26c8ZvyOsOLNJR-z87ZMMWb8l20rnDd8nved30O3R1Tuf3GTCAViW9tst6pZwtMk2_5vU3Gpc6W2JqMwyMsCc4_az0kxkLDNFqJyzK77B69YNmBf10ORpfA1Y585Iauw3TxFYKU5AyQ2dl8fDz13yp8tyLbZ7TKagNGqMQrfbI1fhsEU-8rtOCZ3wALJ6AY-hOhUkDzUxotA58Z3jkAD2GKdjPAXwwJRQ7dVo4C4oATFsbRcbnaRiknO2TzaIs7AGhEWAK50dwBQgWcqWHIghS34UMkKFVoe2Rk_X-yru2oIZcR5rdSuSGRG7IQSSBGz3C1yyQT8RCgsb_B93hf9Idk5eTRTKV0_PZxTvyKsAAlua95YhsVqvavgcEUukPnYT9AQbd2Pk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Successful+Switch+to+Vemurafenib+Plus+Cobimetinib+After+Dabrafenib+Plus+Trametinib+Toxicity+in+BRAFV600E-Mutant+Metastatic+Non%E2%80%93Small-Cell+Lung+Cancer&rft.jtitle=Clinical+lung+cancer&rft.au=Chic%2C+Nuria&rft.au=Mezquita%2C+Laura&rft.au=Aldea%2C+Mihaela&rft.au=Chebib%2C+Ralph&rft.date=2021-01-01&rft.pub=Elsevier+Inc&rft.issn=1525-7304&rft.volume=22&rft.issue=1&rft.spage=e54&rft.epage=e56&rft_id=info:doi/10.1016%2Fj.cllc.2020.07.013&rft.externalDocID=S1525730420302357 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1525-7304&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1525-7304&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1525-7304&client=summon |